Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
RESEARCH TOOLSreports
Bioxcel Therapeutics (BTAI) Stock Price & Analysis
1,274 Followers
BTAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $12.40
Previous Close$1.12
Volume426.29K
Average Volume (3M)590.73K
Market Cap
$42.03M
Enterprise Value$69.88M
Total Cash (Recent Filing)$74.14M
Total Debt (Recent Filing)$101.98M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 06, 2024EPS Estimate
-$0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.18
Shares Outstanding37,530,821
10 Day Avg. Volume427,410
30 Day Avg. Volume590,726
Standard Deviation0.35
R-Squared0.00292
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.59
Price to Sales (P/S)31.00
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue39.79
Enterprise Value/Gross Profit582.30
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$7.00Price Target Upside548.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bioxcel Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical ResultsIgalmi's highest-approved 180µg dose showed no signs of tolerance, tachyphylaxis, or withdrawal in an open-label PMR study involving inpatient adults with frequent episodes of agitation associated with schizophrenia or bipolar disorder.
Market ExpansionImportant implications are expected from the post-marketing requirement study, which could expand the use and commercialization of the product.
Treatment PotentialThe stock affords the potential for significant upside if the company is able to successfully execute and develop the product for agitation in Alzheimer's disease where the unmet need is high.
Bears Say
Clinical DevelopmentBTAI's stock continues to trade near all-time lows, as questions remain surrounding its clinical development plans for BXCL501.
FinancingThe company's cash balance currently cannot support running the two trials through completion.
UncertaintySeveral key questions remain unanswered, including when the study might be initiated and when top-line data could be expected.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.11 and its highest was $12.40 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Currently, no data Available
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Aug 06, 2024 which is in 33 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on May 09, 2024. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.675 by -$0.195.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -$0.72.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 37,530,823 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.675. Following the earnings report the stock price went up 8.491%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at N/A.
---
Bioxcel Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (548.15% Upside)
$7.00 (548.15% Upside)
Blogger Sentiment
Bearish
BTAI Sentiment 67%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 22.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $404.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-54.29%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
---
BTAI Earnings Call
Q1 2024
0:00 / 0:00
---
BTAI Stock 12 Month Forecast
Average Price Target
$7.00
▲(548.15% Upside)
Technical Analysis
Sorrento Therapeutics
―
Kodiak Sciences
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/38 ratings generated profit
1 Year Average Return
+43.96%
reiterated a buy rating 8 days ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of +43.96% per trade.
---